Storia in 2 fonti

Novocure’s electric fields therapy fails key glioblastoma study

Novocure's Optune Gio fails Phase 3 TRIDENT trial in newly diagnosed glioblastoma; overall survival nearly identical in early-use vs. approved arm. Shares drop 17%.

Raccontata da

endpoints.news

benzinga.com

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

endpoints.newsStai leggendo1 mese fa

Novocure’s electric fields therapy fails key glioblastoma study

Novocure's Optune Gio fails Phase 3 TRIDENT trial in newly diagnosed glioblastoma; overall survival nearly identical in early-use vs. approved arm. Shares drop 17%.

originale

benzinga.com1 mese fa

Novocure Brain Cancer Study Shows No Significant Survival Benefit, Stock Tanks - NovoCure (NASDAQ:NVCR)

Novocure's Phase 3 TRIDENT trial missed its primary survival endpoint in glioblastoma but confirmed TTFields safety.

Leggi questa versione → originale

Timeline cronologica

giovedì 18 giugno 2026·endpoints.news
Novocure’s electric fields therapy fails key glioblastoma study
Novocure's Optune Gio fails Phase 3 TRIDENT trial in newly diagnosed glioblastoma; overall survival nearly identical in early-use vs. approved arm. Shares drop 17%.
giovedì 18 giugno 2026·benzinga.com
Novocure Brain Cancer Study Shows No Significant Survival Benefit, Stock Tanks - NovoCure (NASDAQ:NVCR)
Novocure's Phase 3 TRIDENT trial missed its primary survival endpoint in glioblastoma but confirmed TTFields safety.